CV Sciences, Inc. (CVSI)
| Market Cap | 4.03M -43.8% |
| Revenue (ttm) | 12.74M -14.9% |
| Net Income | -2.01M |
| EPS | -0.01 |
| Shares Out | 203.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,154 |
| Open | 0.0206 |
| Previous Close | 0.0300 |
| Day's Range | 0.0200 - 0.0210 |
| 52-Week Range | 0.0150 - 0.1000 |
| Beta | 0.49 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About CV Sciences
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed it... [Read more]
Full Company ProfileFinancial Performance
In 2025, CV Sciences's revenue was $13.79 million, a decrease of -12.20% compared to the previous year's $15.71 million. Losses were -$958,000, -59.98% less than in 2024.
Financial StatementsNews
CV Sciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue declined 7% sequentially to $3 million, with gross margin steady at 48.6% and operating expenses down 7.9%. Positive operating cash flow was achieved, and new product launches and regulatory developments are expected to support future growth.
CV Sciences Earnings release: Q2 2026
CV Sciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
CV Sciences Quarterly report: Q2 2026
CV Sciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results
SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extr...
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids
New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging. SAN D...
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026
SAN DIEGO, CA / ACCESS Newswire / August 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extr...
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
Built on the Company's Health Intelligence™ Approach, the New Products Help Consumers Create Personalized Wellness Routines That Support Overall Health and Long-Term Vitality SAN DIEGO, CA / ACCESS Ne...
CV Sciences Earnings Call Transcript: Q1 2026
Revenue declined 11% year-over-year to $3.2 million, but gross margin improved to 48.9% and operating expenses fell 13%. Adjusted EBITDA loss narrowed to $0.1 million, and positive operating cash flow was achieved. Regulatory and market headwinds persist.
CV Sciences Earnings release: Q1 2026
CV Sciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
CV Sciences Quarterly report: Q1 2026
CV Sciences has published its Q1 2026 quarterly earnings report on May 14, 2026.
CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results
SAN DIEGO, CA / ACCESS Newswire / May 14, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extract...
CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026
SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extract...
CV Sciences Proxy statement: Proxy filing
CV Sciences filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.
CV Sciences Earnings Call Transcript: Q4 2025
Revenue declined to $13.8M in 2025, but gross margin rose to 49% and cost reductions drove positive Q4 adjusted EBITDA. New product launches, acquisitions, and regulatory changes position the company for growth and improved cash flow in 2026.
CV Sciences Annual report: Q4 2025
CV Sciences has published its Q4 2025 annual report on March 26, 2026.
CV Sciences Earnings release: Q4 2025
CV Sciences released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.
CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results
SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026
SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...
CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth
SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, sc...
CV Sciences launches EMPOWR protein, creatine powder
CV Sciences (CVSI) announced the launch of Empowr, a plant-based protein and creatine powder for everyday adults looking to increase daily protein intake for overall wellness. “Empowr” represents a dy...
CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness
With 20g of clean protein, 5g of creatine, and LactoSpore® probiotics, Empowr supports everyday strength, mental energy and digestive balance without dairy or added sugar. Simple, functional nutrition...
CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD
SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...
President Trump says marijuana order ‘not legalization’
President Trump is signing an executive order to reschedule marijuana for “legitimate medical uses.” Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), ...
Trump says looking at reclassifying mariijuana ‘very strongly,’ Bloomberg says
Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IG...
CV Sciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue declined 16% year-over-year to $3.3 million, with gross margin improving to 48.5%. Regulatory uncertainty and out-of-stock issues impacted sales, but cost controls and acquisition integration position the company for positive cash flow and growth in 2026.